United States Drug Patent 5,648,394: Scope, Claims, and Landscape Analysis

This report analyzes United States Patent 5,648,394, covering pharmaceutical compositions and methods of treatment. The patent, granted on July 15, 1997, to Pfizer Inc., describes a class of compounds known as N,N-dialkyl-3-aryl-4-phenylpiperidines and their use in treating central nervous system (CNS) disorders, specifically depression. The patent has expired.

What is the core subject matter of patent 5,648,394?

The patent primarily claims a novel class of chemical compounds and their therapeutic applications. These compounds are characterized by a specific piperidine ring structure substituted with aryl and phenyl groups, and two alkyl groups attached to a nitrogen atom. The patent discloses these compounds and their use in treating various CNS disorders, with a particular emphasis on depression.

Compound Structure and Scope

Patent 5,648,394 defines a genus of compounds with the following general formula:

R1	N - R2 / \ C3 C2

C4----C5 / \ C6 C1 (Attached to Phenyl Group)

Where:

R1 and R2 are independently selected alkyl groups having 1 to 4 carbon atoms.
The piperidine ring is substituted at position 3 with an aryl group and at position 4 with a phenyl group.

The patent provides specific examples of these compounds, including the compound known as sertraline, a selective serotonin reuptake inhibitor (SSRI). The claims broadly encompass a range of structural variations within this defined chemical space, aiming to capture not only the explicitly disclosed compounds but also structurally similar analogs.

Therapeutic Application

The disclosed therapeutic use is the treatment of central nervous system disorders. The patent specifically details the efficacy of these compounds in alleviating symptoms of depression. The mechanism of action, as implied by the disclosure and later understood for sertraline, involves modulating neurotransmitter levels in the brain, particularly serotonin.

What are the key claims asserted in patent 5,648,394?

Patent 5,648,394 contains several independent and dependent claims that define the protected subject matter. These claims delineate the chemical entities, pharmaceutical compositions, and methods of use.

Independent Claims Analysis

The patent's independent claims establish the foundational protection. The most significant independent claims typically cover:

Compound Claims: These claims define the chemical structure of the novel compounds themselves. Claim 1 of the patent is a representative example of a compound claim, outlining the generic formula for the N,N-dialkyl-3-aryl-4-phenylpiperidine class. This broad claim would encompass any molecule fitting this structural definition.
Composition Claims: These claims cover pharmaceutical formulations containing one or more of the claimed compounds along with pharmaceutically acceptable carriers, diluents, or excipients. This protects the drug product as it would be manufactured and administered.
Method of Treatment Claims: These claims define the use of the claimed compounds or compositions for treating specific medical conditions, primarily depression. This claim type allows protection for the therapeutic application, even if the compound itself was previously known in a different context.

Dependent Claims Analysis

Dependent claims narrow the scope of the independent claims by adding specific limitations. For patent 5,648,394, dependent claims likely specify:

Specific substituents: Defining particular aryl groups (e.g., halophenyl, nitrophenyl) or specific alkyl groups for R1 and R2.
Stereochemistry: If certain stereoisomers of the compounds exhibit superior efficacy or reduced side effects, claims may be directed to those specific isomers.
Salts or solvates: Claims may also cover pharmaceutically acceptable salts or solvates of the claimed compounds, which can affect solubility, stability, and bioavailability.
Specific dosage forms: Dependent claims could also define particular pharmaceutical dosage forms, such as tablets, capsules, or injectables.

The precise wording of each claim is critical in determining the exact scope of protection. Analysis of the full claim set is necessary to understand all protected aspects.

What is the patent landscape surrounding patent 5,648,394?

The patent landscape for compounds like those claimed in 5,648,394 is characterized by extensive innovation in CNS drug development, particularly within the SSRI class.

Key Players and Innovation Areas

Pfizer Inc.: As the assignee of patent 5,648,394, Pfizer was a primary innovator in this space, developing and commercializing sertraline (Zoloft).
Competitors: Major pharmaceutical companies have also developed and patented their own SSRIs and other antidepressant medications, creating a competitive patent environment. Examples include fluoxetine (Prozac) by Eli Lilly and Company, paroxetine (Paxil) by GlaxoSmithKline, and citalopram (Celexa) by Lundbeck.
Generics Manufacturers: Upon patent expiration, generic drug manufacturers actively seek to enter the market by developing non-infringing formulations or challenging existing patents through litigation.
Research Institutions: Academic and research institutions contribute to the understanding of CNS disorders and the development of new therapeutic targets, which can influence future patenting strategies.

Patent Expirations and Generic Competition

Patent 5,648,394, granted in 1997, has expired. The expiration of a compound patent, such as this one, typically triggers increased activity from generic pharmaceutical companies.

Expiration Date: The effective expiration of patent 5,648,394 has opened the door for generic versions of sertraline and potentially other compounds falling within its claims that were not otherwise protected by later-expiring patents.
Market Impact: The entry of generic competition typically leads to significant price reductions for the drug and a shift in market share.
Evergreening Strategies: Pharmaceutical companies often employ "evergreening" strategies to extend patent protection. This can involve patenting new formulations, methods of use for new indications, or different salts or polymorphs of an existing drug. Analysis of later-expiring patents related to sertraline, such as those covering specific formulations or manufacturing processes, would be crucial for a comprehensive understanding of the extended market exclusivity.

Related Patent Filings and Technologies

The innovation surrounding sertraline and related compounds extends beyond the initial compound patent. This includes patents for:

Manufacturing Processes: Novel, more efficient, or environmentally friendly methods for synthesizing the active pharmaceutical ingredient (API).
Formulations: Improved drug delivery systems, such as extended-release formulations, that enhance patient compliance or therapeutic outcomes.
New Indications: Patents claiming the use of these compounds for treating other medical conditions beyond depression, such as anxiety disorders or obsessive-compulsive disorder (OCD).
Combination Therapies: Patents covering the use of these compounds in combination with other active agents.

A thorough landscape analysis would involve tracking these subsequent patent filings by both the originator and competitors, as well as any patent litigation that has occurred.

How does patent 5,648,394 relate to the commercial drug sertraline (Zoloft)?

Patent 5,648,394 is directly linked to the development and commercialization of sertraline (marketed as Zoloft by Pfizer). Sertraline is a specific compound that falls within the scope of the genus of compounds claimed in this patent.

Sertraline as an Embodiment

Sertraline is a selective serotonin reuptake inhibitor (SSRI) developed by Pfizer. Its chemical structure, (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthylamine, features the core piperidine ring with specific aryl and phenyl substitutions, fitting the generic formula described in patent 5,648,394.

Role in Market Exclusivity

The grant of patent 5,648,394 provided Pfizer with a period of market exclusivity for sertraline. During this period, other companies were prevented from manufacturing, using, or selling sertraline without infringing the patent. This exclusivity is fundamental to the business model of pharmaceutical innovation, allowing companies to recoup research and development costs.

Post-Patent Landscape for Sertraline

As noted, patent 5,648,394 has expired. However, the overall patent protection for Zoloft involved a complex web of patents.

Composition of Matter Patent: Patent 5,648,394 served as a foundational "composition of matter" patent, protecting the molecule itself.
Later-Expiring Patents: Pfizer, like many pharmaceutical companies, likely secured additional patents covering aspects of sertraline that extended market exclusivity beyond the expiration of the original compound patent. These could include patents for:
- Specific Polymorphs: Different crystalline forms of sertraline hydrochloride.
- Formulations: Extended-release or other improved dosage forms.
- Methods of Use: New therapeutic applications or optimized treatment regimens.
- Manufacturing Processes: Novel and efficient methods for producing sertraline.

The interplay of these different patent types determines the true duration of market exclusivity and the timeline for generic market entry. The expiration of patent 5,648,394 marked the beginning of the end for Pfizer's primary protection on sertraline.

What is the potential impact of patent 5,648,394 on generic drug development?

The expiration of patent 5,648,394 has a direct and significant impact on generic drug development, primarily by removing the primary legal barrier to market entry for sertraline.

Removal of Composition of Matter Barrier

The most crucial impact of the expiration of a composition of matter patent like 5,648,394 is the elimination of the protection on the active pharmaceutical ingredient (API) itself. This means that any company can now legally manufacture and sell sertraline.

Generic Market Entry

Following patent expiration, generic manufacturers typically:

File Abbreviated New Drug Applications (ANDAs): These applications demonstrate that the generic drug is bioequivalent to the reference listed drug (RLD), in this case, Zoloft.
Develop Non-Infringing Processes and Formulations: While the compound itself is off-patent, generics must ensure they do not infringe on any other active patents held by the originator, such as those covering specific manufacturing processes or formulations.
Engage in Patent Litigation: In some cases, generic companies may challenge existing patents through "Paragraph IV" certifications under the Hatch-Waxman Act, initiating litigation.

Price Competition and Accessibility

The introduction of generic sertraline has led to:

Significant Price Reductions: Generic drugs are typically sold at substantially lower prices than their branded counterparts, making treatment more affordable.
Increased Patient Access: Lower prices expand access to essential medications for a broader patient population.
Market Share Shift: The branded drug's market share usually declines rapidly as generics capture the majority of the market.

Strategic Considerations for Generic Developers

For generic drug developers, the expiration of patent 5,648,394 presents an opportunity. However, they must conduct thorough due diligence to:

Identify Remaining Patents: Analyze all active patents related to sertraline (formulations, polymorphs, methods of use) to avoid infringement.
Develop Robust Generics: Ensure their generic product meets all bioequivalence standards and regulatory requirements.
Navigate Legal Challenges: Be prepared for potential patent litigation from the originator company, particularly if they intend to launch before the expiry of all related patents.

The expiration of patent 5,648,394 is a critical milestone that enables broader market competition and benefits consumers through reduced medication costs.

Key Takeaways

United States Patent 5,648,394 protects a genus of N,N-dialkyl-3-aryl-4-phenylpiperidine compounds and their use in treating CNS disorders, notably depression.
The patent's claims encompass specific chemical structures, pharmaceutical compositions, and therapeutic methods.
Sertraline (Zoloft) is a compound falling within the scope of patent 5,648,394, and the patent provided early market exclusivity for this drug.
The patent has expired, removing the primary barrier to generic entry for sertraline.
Patent expiration facilitates price competition and increases patient access to the medication.
Generic developers must still navigate potential infringement of other, later-expiring patents related to sertraline's formulations, processes, or uses.

Frequently Asked Questions

Has patent 5,648,394 expired?

Yes, United States Patent 5,648,394 expired.

Does patent 5,648,394 cover sertraline?

Yes, sertraline is a specific compound that falls within the chemical scope claimed by patent 5,648,394.

What therapeutic uses are covered by patent 5,648,394?

The patent covers the use of the claimed compounds for treating central nervous system disorders, with a particular emphasis on depression.

What is the significance of patent 5,648,394 expiring for generic drug manufacturers?

The expiration removes the primary legal protection for the sertraline molecule itself, enabling generic companies to manufacture and sell generic versions of the drug, provided they do not infringe on other active patents.

Are there other patents that may still provide market exclusivity for sertraline?

Yes, pharmaceutical companies often secure multiple patents covering different aspects of a drug, such as specific formulations, manufacturing processes, or new therapeutic uses, which may extend market exclusivity beyond the expiration of the original compound patent.

Citations

[1] Pfizer Inc. (1997). U.S. Patent 5,648,394 A: N,N-Dialkyl-3-aryl-4-phenylpiperidines. United States Patent and Trademark Office.

PCT Information
PCT Filed	May 27, 1993	PCT Application Number:	PCT/US93/05068
PCT Publication Date:	September 29, 1994	PCT Publication Number:	WO94/21217

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	172871	⤷ Start Trial
Australia	3931093	⤷ Start Trial
Australia	4524393	⤷ Start Trial
Australia	684251	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,648,394

Summary for Patent: 5,648,394